Proven track record of over twenty five years as a senior executive leading life sciences companies spanning biotechnology, diagnostics, medical devices, and high-technology companies in North America and Europe. Bernard leads senior management teams through a sustained focus on strategy, rapid scale up and increasing talent depth to expand markets served.Currently as COO of Cardiol Therapeutics, a clinical-stage biotechnology company developing anti-inflammatory therapies for the treatment of cardiovascular disease where he leads strategic operations.Founder and CEO of a highly successful drug delivery company that he led from R&D through to commercialization, an exponential growth rate and its eventual acquisition by Eli Lily.As Chair of the Board of Altus Assessments, he guided its spinout from the university and its subsequent rapid growth to become market leader in US and Canada. As Chair of the Board and CEO of AndersDx (UK), he led its turnaround and subsequent growth to market leader.He is currently Chair of the Board of Front Line Medical Technologies (Canada), a vascular trauma company and board director of Aventamed (Ireland). Bernard was Senior Vice President, Operations for Vasogen (Canada), as well as head of UK operations for a technology multinational where he scaled its operations exponentially and delivered multifold improvements in quality and financial performance.He was CEO of a Glaucoma, Alzheimer’s and an In-Vitro Diagnostics company and prior to that head of R&D for a global Neonatology and Paediatrics company. Over his career, he has delivered exceptional results in fast growing independent growth companies and corporate roles focused on increasing innovation, accelerating and sustaining growth.In addition to his corporate roles, he serves as an external independent expert reviewer on public sector life science investment programs and as a mentor and adviser to university technology transfer offices and innovation accelerators.